Insight

Jill Feldman Highlighted COCOON Trial PRO Data on Quality of Life at ASCO 2025

Mark Wildgust/X

Jun 3, 2025, 15:11

Jill Feldman Highlighted COCOON Trial PRO Data on Quality of Life at ASCO 2025

Jill Feldman, Co-Founder of EGFR Resister, shared a post on X by , Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, adding:

“Grateful to Johnson and Johnson Innovation for the opportunity to be the lead author on COCOON trial PRO data at ASCO 2025.

It meant a lot to be a co-investigator and true partner and help shape the secondary endpoint to measure what matters to patients (Quality of Life matters)!”

Quoting Mark Wildgust‘s post:

“Great to see Jill Feldman present results from COCOON here at ASCO 2025 on quality of life and prevention of skin reactions. At J and J Innovative Medicine we work collaboratively with all in the medical community to advance care for patients.”

More posts featuring Jill Feldman on OncoDaily.

ASCO 2025 cancer cancer care COCOON trial EGFR Resister J and J Innovative Medicine Jill Feldman Johnson and Johnson Innovation Mark Wildgust OncoDaily Oncology patient care quality of life The Janssen Pharmaceutical Companies of Johnson and Johnson

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment